Updated: Dec 5, 2020
Is Remdesivir the answer?
There is a worldwide rush to discover a vaccine. On May 1st, Trump announced that he was using the Emergency Use Authorization (EUA) from the Food and Drug Administration to release the drug Remdesivir for the treatment of COVID-19 patients. According to new research published in the Journal of Biological Chemistry, remdesivir has shown promise in stopping the spread of this virus in affected patients.
The EUA is allowing the distribution of remdesivir in the United States since there are currently no adequate, approved, or available alternative treatments to aid COVID-19 patients. In other words, benefits using this experimental drug outweigh the known and potential risks of the drug's use. And will be used to treat suspected/ laboratory-confirmed COVID-19 in adults and children who have been hospitalized with low blood oxygen levels, needing oxygen therapy, or using a mechanical ventilator, according to a media release by the FDA.
The University of Washington school of Medicine was one of the testing sites chosen to test the effectiveness of remdesivir by the National Institutes of Health. The use of remdesivir on patients with COVID-19 shortened recovery time and lowered the death rate according to their clinical trials, said Dr. Helen Chu, assistant professor of medicine at the UW School of Medicine, in a news release.
"It's really a gamechanger for the field to know first of all having an anti-viral drug that works to prevent real clinical outcomes, to improve clinical outcomes is just so important," Dr. Chu said.
The COVID-19 disease has been reported in approximately 210 countries and territories worldwide, according to Statistica. In the United States, the first cases detected were from people entering the U.S. Person-to-person spread was subsequently reported among close contacts of returned travelers. Widespread infection of this virus is spreading. However, how many of these new patients became exposed to the virus is still not known.